Caenorhabditis elegans models of human neurodegenerative diseases: A powerful tool to identify molecular mechanisms and novel therapeutic targets

Source Book of Models for Biomedical Research

Volumn , Issue , 2008, Pages 91-101

  Nass, Richard ^a   Chen, Lihsia ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

6 OHDA; Alzheimer's disease; C. elegans; Genetics; Hereditary spastic paraplegia; High throughput screens; Huntington's disease; Nematode; Parkinson's Disease

Indexed keywords

EID: 77957888561     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-59745-285-4_12     Document Type: Chapter

References (147)

1. The C. elegans Sequencing Consortium. Genome sequence of the nematode C. elegans: A platform for investigating biology. Science 1998;282:2012-2018.
2. Hiller LW, Coulson A, Murray JI, Bao Z, Sulston JE, Waterson RH. Genomics in C. elegans: So many genes, such a little worm. Genome Res 2006;15:1651-1660.
3. Rand JB, Nonet ML. Synaptic transmission. In: Riddle DL, Blumenthal T, Meyer BJ, Priess JR, Eds. C. elegans II. New York: Cold Spring Harbor Laboratory Press, 1997:611-643.
4. Thomas, JH, Lockery SH. Neurobiology. In: Hope IA, Ed. C. elegans: A Practical Approach. New York: Oxford University Press, 1999:143-179.
5. Bargmann CI. Neurobiology of the Caenorhabditis elegans genome. Science 1998;282:2028-2033.
6. Nonet ML. Studying mutants that affect neurotransmitter release in C. elegans. In: Bellen HJ, Ed. Neurotransmitter Release. New York: Oxford University Press. 1999.
7. Nass R, Blakely RB. The Caenorhabditis elegans dopaminergic system: Opportunities for insights into dopamine transport and neurodegeneration. Annu Rev Pharmacol Toxicol 2003;43:521-544.
8. Riddle DL, Blumenthal T, Meyer BJ, Priess JR, Eds. C. elegans II. New York: Cold Spring Harbor Laboratory Press, 1997.
9. Wood, WB. Introduction to C. elegans. In: WB Wood, Ed. The Nematode Caenorhabditis elegans. New York: Cold Spring Harbor Laboratory Press, 1988:1-16.
10. Link EM, Hardiman G, Sluder AE, Johnson CD, Liu LX. Therapeutic target discovery using Caenorhabditis elegans. Pharmacogenomics 2000;1:203-217.
11. Kaletta T, Hengartner MO. Finding function in novel targets: C. elegans as a model organism. Nat Rev Drug Discov 2006;5: 387-398.
12. Bloom L. Genetic and molecular analysis of genes required for axon outgrowth in Caenorhabditis elegans. PhD. Thesis, Massachusetts Institute of Technology, Cambridge, MA, 1993.
13. Buechner M, Hall DH, Bhatt H, Hedgecock EM. Cystic canal mutants in Caenorhabtitis elegans are defective in the apical membrane domain of the renal (excretory) cell. Dev Biol 1999;214:227-241.
14. Christensen M, Estevez A, Yin X, Fox R, Morrison R, McDonnell M, Gleason C, Miller DM, Strange K. A primary culture system for functional analysis of C. elegans neurons and muscle cells. Neuron 2002;33:503-514.
15. Carvelli L, McDonald PW, Blakely RD, Defelice LJ. Dopamine transporters depolarize neurons by a channel mechanism. Proc Natl Acad Sci USA 2004;101:16046-16051.
16. Bianchi L, Driscoll M. Culture of embryonic C. elegans cells for electrophysiological and pharmacological analyses. In: The C. elegans Research Community, Ed. Wormbook. http://www. wormbook.org, 2006.
17. Fox RM, Von Stetina SE, Barlow SJ, Shaffer C, Olszewski KL, Moore JH, Dupuy D, Vidal M, Miller, DM 3rd. A gene expression fi ngerprint of C. elegans embryonic motor neurons. BMC Genomics 2005;6:42.
18. Jorgensen EM, Mango SE. The art and design of genetic screens: Caenorhabditis elegans. Nat Rev Genet 2002;3:356-369.
19. Wicks SR, Yeh RT, Gish WR, Waterston RH, Plasterk RH. Rapid gene mapping in Caenorhabditis elegans using a high density polymorphism map. Nat Genet 2001;28:160-164.
20. See the Caenorhabditis elegans WWW Server at http://elegans.swmed. edu/.
21. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998;391:806-811.
22. Montgomery MK, Xu S, Fire A. RNA as a target of double-stranded RNA-mediated genetic interference in Caenorhabditis elegans. Proc Natl Acad Sci USA 1998;95:15502-15507.
23. Timmons L, Fire A. Specific interference by ingested dsRNA. Nature 1998;395:854.
24. Maeda I, Kohara Y, Yamamoto M, Sugimoto A. Large-scale analysis of gene function in Caenorhabditis elegans by high-throughput RNAi. Curr Biol 2001;11:171-176.
25. Kamath RS, Fraser AG, Dong Y, Poulin G, Durbin R, Gotta M, Kanapin A, Le Bot N, Moreno S, Sohrmann M, et al. Systematic functional analysis of the Caenorhabditis elegans genome using RNAi. Nature 2003;421:231-237.
26. Kamath RS, Ahringer J. Genome-wide RNAi screening in Caenorhabditis elegans. Methods 2003;30:313-321.
27. Buckingham SD, Esmaeili B, Wood M, Sattelle DB. RNA interference: From model organisms towards therapy for neural and neuromuscular disorders. Hum Mol Genet 2004;13(Spec. No. 2): R275-R288.
28. Mello C, Fire A. DNA transformation. Methods Cell Biol 1995;48:451-482.
29. Chalfie M, Tu Y, Euskirchen G, Ward WW, Prasher DC. Green fl uorescent protein as a marker for gene expression. Science 1994;263:802-805.
30. Miller DM III, Desai NS, Hardin DC, Piston DW, Patterson GH, et al. Two color GFP expression for C. elegans. BioTechniques 1999;26:914-921.
31. White JG, Southgate E, Thompson JN, Brenner S. The structure of the nervous system of the nematode Caenorhabditis elegans. Philos Trans R Soc London B Biol Sci 1986;B314:1-340.
32. Mitchell SL, Kiely DK, Kiel DP, Lipsitz LA. The epidemiology, clinical characteristics, and natural history of older nursing home residents with a diagnosis of Parkinson's disease. J Am Geriatr Soc 1996;44:394:99.
33. Yahr MD, Bergman K, Eds. Advances in Neurology: Parkinson's Disease. New York: Raven, 1986.
34. Polymeropoulos MH, et al. Mutation in the alpha-synuclein gene identifi ed in families with Parkinson's disease. Science 1997;276: 2045-2047.
35. Forloni G, Bertani I, Calella AM, Thaler F, Invernizzi R. Alphasynuclein and Parkinson's disease: Selective neurodegenerative effect of alpha-synuclein fragment on dopaminergic neurons in vitro and in vivo. Ann Neurol 2000;47:632-640.
36. Masliah E, et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: Implications for neurodegenerative disorders. Science 2000;287:1265-1269.
37. Jenner P. Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov Disord 1998;13:24-34.
38. Witt SN, Flower TR. α-Synuclein, oxidative stress and apoptosis from the perspective of a yeast model of Parkinson's disease. FEMS Yeast Res 2006;6(8):1107-1110.
39. Marfin I, Vallejo J. Parkinson disease: From cellular and animal models to genomics Curr Genomics 2005;6:241-250.
40. Sauer H, Oertel WH. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxdopamine: A combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 1994;59:401-415.
41. Glinka Y, Gassen M, Youdim MBH. Mechanism of 6-hydroxydopamine neurotoxicity. J Neural Transm 1997;50:55-66.
42. Hoglinger GU, Oerte WH, Hirsch EC. The rotenone model of parkinsonism-the five year inspection. J Neural Transm Suppl 2006;70:269-270.
43. Kitayama S, Shimada S, Uhl GR. Parkinsonism-inducing neurotoxin MPP+: Uptake and toxicity in nonneuronal COS cells expressing dopamine transporter cDNA. Ann Neurol 1992;32:109-111.
44. Gainetdinov RR, Jones SR, Fumagalli F, Wightman RM, Caron MG. Re-evaluation of the role of the dopamine transporter in dopamine system homeostasis. Brain Res Brain ResRev 1998;26: 148-153.
45. Kitada T, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998;392:605-608.
46. Leroy E, Anastasopoulos D, Konitsiotis S, Lavedan C, Polymeropoulos MH. Deletions in the parkin gene and genetic heterogeneity in a greek family with early onset Parkinsons disease. Hum Genet 1998;103:424-427.
47. Bonifati V, Oostra BA, Heutink P. Linking DJ-1 to neurodegeneration offers novel insights for understanding the pathogenesis of Parkinson's disease. J Mol Med 2004;82:163-174.
48. Gilks WP, Abou-Seiman PM, Gandhi S, Jain S, Singleton A, Lees AJ, Shaw K, Bhatia KP, Bonifati V, Quinn NP, Lynch J, Healy DG, Holton JL, Revesz T, Wood NW. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 2005;365:415-416.
49. Valente EM, Abou-Sleiman PM, Caputo B, Muqit MM, Harvey K, Gispert S, Ali Z, Del Turco D, Bentivoglio AR, Healy DG, Albanese A, Nussbaum R, Gonzalez-Maldonado R, Deller T, Salvi S, Cortelli P, Gilks WP, Latchman DS, Harvey RJ, Dallapiccola B, Auburger G, Wood NW. Hereditary early-onset Parkinson's disease caused by mutations in pink-1. Science 2004;304:1158-1160.
50. Paisan-Ruiz C, Jain S, Evan EW, Gilks WP, Simon J, van der Brug M, Lopez de Munain A, Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR, Nicholl D, Carrera IM, Pena AS, de Silva R, Lees A, Marti-Masso JF, Perez-Tur J, Wood NW, Singleton AB. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004;44:595-600.
51. Greenbaum EA, Graves CL, Mishizen-Eberz AJ, Lupoli MA, Lynch DR, Englander SW., Axelsen PH, Giasson BI. The E46K mutation in alpha-synculein increases amyloid fibril formation. J Biol Chem 2005;280:7800-7807.
52. Lee FJ, Liu F, Pristupa ZB, Niznik HB. Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J 2001;15:916-926.
53. Nass R, Miller DM, Blakely RD. C. elegans: A novel pharmacogenetic model to study Parkinson's disease. Parkinsonism Relat Disord 2001;7:185-191.
54. Nass R, Hall DH, Miller DM 3rd, Blakely RD. Neurotoxin-induced degeneration of dopamine neurons in Caenorhabditis elegans. Proc Natl Acad Sci USA 2002;99:3264-3269.
55. Braungart E, Gerlach M, Riederer P, Baumeister R, Hoener MC. Caenorhabditis elegans MPP+ model of Parkinson's disease for high-throughput drug screenings. Neurodegener Dis2004;1(4-5):175-183.
56. Wintle RF, Van Tol HHM. Dopamine signaling in Caenorhabditis elegans-potential for parkinsonism research. Parkinsonism Relat Disord 2001;7:177-183.
57. Westlund B, Stilwell G, Sluder A. Invertebrate disease models in neurotherapeutic discovery. Curr Opin Drug Discov 2004;7:169-178.
58. Lakso M, Vartianen S, Moilanen AM, Sirvio J, Thomoas JH, Nass R, Blakely RD, Wong G. Dopaminergic neuronal loss and motor defi cits in Caenorhabditis elegans overexpressing human α-synuclein. J Neurochem 2003;86:165-172.
59. Kuwahara T, Koyama A, Gengyo-Ando K, Masuda M, Kowa H, Tsunoda M, Mitani S, Iwatsubo T. Familial Parkinson mutant α-synuclein causes dopamine neuron dysfunction in transgenic Caenorhabditis elegans. J Biol Chem 2006;281:334-340.
60. Cooper AA, Gitler AD, Casikar A, Haynes CM, Hill KJ, et al. α-Synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 2006;313:324-328.
61. Vartiainen S, Pehkonen P, Lakso M, Nass R, Wong G. Identifi cation of gene expression changes in transgenic C. elegans overexpressing human α-synuclein. Neurobiol Dis 2006;22:477-486.
62. Springer W, Hoppe T, Schmidt E, Baumeister R. A Caenorhabditis elegans parkin mutant with altered solubility couples α-synuclein aggregation to proteotoxic stress. Hum Mol Genet 2005;14: 3407.
63. Ved R, Saha S, Westlund B, Perier C, Bumam L, Sluder A, Hoener M, Rodrigues CMP, Alfonso A, Steer C, Liu L, Przedborski S, Wolozin B. Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of a-synuclein, parkin, and DJ-1 in Caenorhabditis elegans. J Biol Chem 2005;280:42655-42668.
64. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 2006;368:387-403.
65. Glenner GG, Wong CW. Alzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 1984;122:1131-1135.
66. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Greschik KH, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987;325:733-736.
67. Goate A, Chartier-Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349:704-776.
68. Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995;375:754-760.
69. Levy-Lahad E, Wasco W, Poorkaj P, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995;269:973-977.
70. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 2002;297:353-356.
71. Spires TL, Hyman BT. Transgenic models of Alzheimer's disease: Learning from animals. NeuroRx 2005;2:423-437.
72. Coulson EJ, Paliga K, Beyreuther K, Masters CL. What the evolution of the amyloid protein precursor supergene family tells us about its function. Neurochem Int 2000;36:175-184.
73. Daigle I, Li C. apl-1, a Caenorhabditis elegans gene encoding a protein related to the human beta-amyloid protein precursor. Proc Natl Acad Sci USA 1993;90:12045-12049.
74. Rosen DR, Martin-Morris L, Luo LQ, White K. A Drosophila gene encoding a protein resembling the human beta-amyloid protein precursor. Proc Natl Acad Sci USA 1989;86:2478-2482.
75. WormBase web site, http://www.wormbase.org, release WS163.
76. Levitan D, Greenwald I. Facilitation of lin-12-mediated signalling by sel-12, a Caenorhabditis elegans S182 Alzheimer's disease gene. Nature 1995;377:351-354.
77. Baumeister R, Leimer U, Zweckbronner I, Jakubek C, Grunberg J, Haass C. Human presenilin-1, but not familial Alzheimer's disease (FAD) mutants, facilitate Caenorhabditis elegans Notch signalling independently of proteolytic processing. Genes Funct 1997;1:149-159.
78. Levitan D, Doyle TG, Brousseau D, Lee MK, Thinakaran G, Slunt HH, Sisodia SS, Greenwald I. Assessment of normal and mutant human presenilin function in Caenorhabditis elegans. Proc Natl Acad Sci USA 1996;93:14940-14944.
79. Li X, Greenwald I. HOP-1, a Caenorhabditis elegans presenilin, appears to be functionally redundant with SEL-12 presenilin and to facilitate LIN-12 and GLP-1 signaling. Proc Natl Acad Sci USA 1997;94:12204-12209.
80. Goutte C, Hepler W, Mickey KM, Priess JR. aph-2 encodes a novel extracellular protein required for GLP-1-mediated signaling. Development 2000;127:2481-2492.
81. Yu G, Nishimura M, Arawaka S, Levitan D, Zhang L, et al. Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing. Nature 2000;407:48-54.
82. Link CD. Expression of human b-amyloid peptide in transgenic Caenorhabditis elegans. Proc Natl Acad Sci USA 1995;92:9368-9372.
83. Fay DS, Fluet A, Johnson CJ, Link CD. In vivo aggregation of beta-amyloid peptide variants. J Neurochem 1998;71:1616-1625.
84. Yatin SM, Varadarajan S, Link CD, Butterfield DA. In vitro and in vivo oxidative stress associated with Alzheimer's amyloid betapeptide (1-42). Neurobiol Aging 1999;20:325-330; discussion 339-342.
85. Drake J, Link CD, Butterfield DA. Oxidative stress precedes fi brillar deposition of Alzheimer's disease amyloid beta-peptide (1-42) in a transgenic Caenorhabditis elegans model. Neurobiol Aging 1999;24:415-420.
86. Boyd-Kimball D, Poon HF, Lynn BC, Cai J, Pierce WM Jr, Klein JB, Ferguson J, Link CD, Butterfield DA. Proteomic identifi cation of proteins specifically oxidized in Caenorhabditis elegans expressing human Abeta(1-42): Implications for Alzheimer's disease. Neurobiol Aging 2006;27:1239-1249.
87. Link CD, Taft A, Kapulkin V, Duke K, Kim S, Fei Q, Wood DE, Sahagan BG. Gene expression analysis in a transgenic Caenorhabditis elegans Alzheimer's disease model. Neurobiol Aging 2003;24:397-413.
88. Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA 1997;278:1327-1332.
89. Smith JV, Luo Y. Elevation of oxidative free radicals in Alzheimer's disease models can be attenuated by Ginkgo biloba extract EGb 761. J Alzheimers Dis 2003;5:287-300.
90. Kraemer BC, Zhang B, Leverenz JB, Thomas JH, Trojanowski JQ, Schellenberg GD. Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy. Proc Natl Acad Sci USA 2003;100:9980-9985.
91. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998;393:702-705.
92. Kraemer BC, Burgess JK, Chen JH, Thomas JH, Schellenberg GD. Molecular pathways that influence human tau-induced pathology in Caenorhabditis elegans. Hum Mol Genet 2006;15:1483-1496.
93. Lucas JJ, Hernandez F, Gomez-Ramos P, Moran MA, Hen R, Avila J. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J 2001;20:27-39.
94. Wang H, Lim PJ, Yin C, Rieckher M, Vogel BE, Monteiro MJ. Suppression of polyglutamine-induced toxicity in cell and animal models of Huntington's disease by ubiquilin. Hum Mol Genet 2006;15:1025-1041.
95. Zoghbi HY, Orr HT. Glutamine repeats and neruodegeneration. Annu Rev Neurosci 2000;23:217-247.
96. Arrasate M, Mitra S, Schweitzer ES, Sega MR, Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004;431:805-810.
97. Bowman AB, Yoo SY, Dantuma NP, Zoghbi HY. Neuronal dysfunction in a polyglutamine disease model occurs in the absence of ubiquitin-proteosome system impairment and inversely correlates with the degree of nuclear inclusion formation. Hum Mol Genet 2005;14:679-691.
98. The Huntington Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72:971-983.
99. Velier J, Kim M, Schwarz C, Kim TW, Sapp E, Chase K, et al. Wild-type and mutant huntingtins function in vesicle traffi cking in the secretory and endocytotic pathways. Exp Neurol 1998;152:34-40.
100. Nasir J, Floresco SB, O'Kusky JR, Diewert VM, Richmond JM, Zeisler J. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 1995;81:811-823.
101. Bence NF, Sampat RM, Kopita RR. Impairment of the ubiquitinproteosome system by protein aggregation. Science 2001;292:1552-1555.
102. Waelter S, Boeddrich A, Lurz R, et al. Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. Mol Biol Cell 2001;12:1393-1407.
103. Cepeda C, Hurst RS, Calvert CR, et al. Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J Neurosci 2003;23: 961-969.
104. Lee S, Kim M. Aging and neurodegeneration: Molecular mechanisms of neuronal loss in Huntington's disease. Mech Ageing Dev 2006;127:432-435.
105. Faber PW, Alter JR, MacDonald ME, Hart AC. Polyglutaminemediated dysfunction and apoptotic death of a Caenorhabditis elegans sensory neuron. Proc Natl Acad Sci USA 1999;96:179-184.
106. Parker JA, Connolly JB, Wellington C, Hayden M, Dausset J, Neri C. Expanded polyglutamines in Caenorhabditis elegans cause axonal abnormalities and severe dysfunction of PLM mechanosensory neurons without cell death. Proc Natl Acad Sci USA 2001;98:13318-13323.
107. Brignull HR, Moore FE, Tang SJ, Morrimoto RI. Polyglutamine proteins at the pathogenic threshold display neuron-specific aggregation in a pan-neuronal Caenorhabditis elegans model J Neurosci 2006;26:7597-7606
108. Satyal SH, Schmidt E, Kitagawa K, Sondheimer N, Lindquist S, Kramer JM, Morimoto RI. Polyglutamine aggregates alter protein folding homeostasis in Caenorhabditis elegans. Proc. Natl Acad Sci USA 2000;97:5750-5755.
109. Morley JF, Brignull HR, Weyers JJ, Morimoto RI. The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans. Proc Natl Acad Sci USA 2002;99:10417-10422.
110. Hsu AL, Murphy CT, Kenyon C. Regulation of aging and agerelated disease by DAF-16 and heat-shock factor. Science 2003;300:1142-1145.
111. Caldwell GA, Songsong C, Sexton EG, Gelwix CC, Bevel JP, Caldwell KA. Suppression of polyglutamine-induced protein aggregation in Caenorhabditis elegans by torsin proteins. Hum Mol Genet 2003;12:307-319.
112. Nollen EAA, Garcia SM, van Haaften G, Kim S, Chavez A, Morimoto RI, Plasterk RHA. Genome-wide RNA interference screen identifies previously undescribed regulators of polyglutamine aggregation. Proc Natl Acad Sci USA 2004;101:6403-6408.
113. Fink JK. Hereditary spastic paraplegia: Nine genes and counting. Arch Neurol 2003;60:1045-1049.
114. Behan W, Maia M. Strumpell's familial spastic paraplegia: Genetics and neuropathology. J Neurol Neurosurg Psychiatry 1974;37:8-20.
115. Rugarli EI, Langer T. Translating m-AAA protease function in mitochondria to hereditary spastic paraplegia. Trends Mol Med 2006;12:262-269.
116. Kenwrick S, Watkins A, De Angelis E. Neural cell recognition molecule L1: Relating biological complexity to human disease mutations. Hum Mol Genet 2000;6:879-886.
117. Yamasaki M, Arita N, Hiraga S, Izumoto S, Morimoto K, Nakatani S, Fujitani K, Sato N, Hayakawa T. A clinical and neuroradiological study of X-linked hydrocephalus in Japan. J Neurosurg 1995;83:50-55.
118. Dahme M, Bartsch U, Martini R, Anliker B, Schachner M, Mantei N. Disruption of the mouse L1 gene leads to malformations of the nervous system. Nat Genet 1997;17:346-349.
119. Chen L, Ong B, Bennett V. LAD-1, the Caenorhabditis elegans L1CAM homologue, participates in embryonic and gonadal morphogenesis and is a substrate for fibroblast growth factor receptor pathway-dependent phosphotyrosine-based signaling. J Cell Biol 2001;154:841-855.
120. Hutter H, Vogel BE, Plenefisch JD, Norris CR, Proenca RB, Spieth J, Guo C, Mastwal S, Zhu X, Scheel J, et al. Conservation and novelty in the evolution of cell adhesion and extracellular matrix genes. Science 2000;287:989-994.
121. Sasakura H, Inada H, Kuhara A, Fusaoka E, Takemoto D, Takeuchi K, Mori I. Maintenance of neuronal positions in organized ganglia by SAX-7, a Caenorhabditis elegans homologue of L1. EMBO J 2005;24:1477-1488.
122. Wang X, Kweon J, Larson S, Chen L. A role for the C. elegans L1CAM homologue lad-1/sax-7 in maintaining tissue attachment. Dev Biol 2005;284:273-291.
123. Aurelio O, Hall DH, Hobert O. Immunoglobulin-domain proteins required for maintenance of ventral nerve cord organization. Science 2002;295:686-690.
124. Fransen E, D'Hooge R, Van Camp G, Berhoye M, Sijbers J, Reyniers E, Soriano P, Hall SG, Bieber AJ. Mutations in the Drosophila neuroglian cell adhesion molecule affect motor neuron pathfi nding and peripheral nervous system patterning. J Neurobiol 1997;32:325-340.
125. Hirokawa N, Takemura R. Molecular motors and mechanisms of directional transport in neurons. Nat Rev Neurosci 2005;6:201-214.
126. Reid E, Kloos M, Ashley-Koch A, Hughes L, Bevan S, Svenson IK, Graham FL, Gaskell PC, Dearlove A, Pericak-Vance MA, Rubinsztein DC, Marchuk DA. A kinesin heavy chain (KIF5A) mutation in hereditary spastic paraplegia (SPG10). Am J Hum Genet 2002;71: 1189-1194.
127. Hazan J, Fonknechten N, Mavel D, Paternotte C, Samson D, et al. Spastin, a new AAA protein, is altered in the most frequent form of autosomal dominant spastic paraplegia. Nat Genet 1999;23:296-303.
128. Evans KJ, Gomes ER, Reisenweber SM, Gundersen GG, Lauring BP. Linking axonal degeneration to microtubule remodeling by Spastin-mediated microtubule severing. J Cell Biol 2005;168:599-606.
129. Yakushiji Y, Yamanaka K, Ogura T. Identification of a cysteine residue important for the ATPase activity of C. elegans fi dgetin homologue. FEBS Lett 2004;578:191-197.
130. Evans K, Keller C, Pavur K, Glasgow K, Conn B, Lauring B. Interaction of two hereditary spastic paraplegia gene products, spastin and atlastin, suggests a common pathway for axonal maintenance. Proc Natl Acad Sci USA 2006;103:10666-10671.
131. Sanderson CM, Connell JW, Edwards TL, Bright NA, Duley S, Thompson A, Luzio JP, Reid E. Spastin and atlastin, two proteins mutated in autosomal-dominant hereditary spastic paraplegia, are binding partners. Hum Mol Genet 2006;15:307-318.
132. Patel H, Cross H, Proukakis C, Hershberger R, Bork P, Ciccarelli FD, Patton MA, McKusick VA, Crosby AH. SPG20 is mutated in Troyer syndrome, an hereditary spastic paraplegia. Nat Genet 2002;31:347-348.
133. Ciccarelli FD, Proukakis C, Patel H, Cross H, Azam S, Patton MA, Bork P, Crosby AH. The identification of a conserved domain in both spartin and spastin, mutated in hereditary spastic paraplegia. Genomics 2003;81:437-441.
134. Lu J, Rashid F, Byrne PC. The hereditary spastic paraplegia protein spartin localises to mitochondria. J Neurochem 2006;98:1908-1919.
135. Robay D, Patel H, Simpson MA, Brown NA, Crosby AH. Endogenous spartin, mutated in hereditary spastic paraplegia, has a complex subcellular localization suggesting diverse roles in neurons. Exp Cell Res 2006;312:2764-2777.
136. Casari G, De Fusco M, Ciarmatori S, Zeviani M, Mora M, Fernandez P, De Michele G, Filla A, Cocozza S, Marconi R, Durr A, Fontaine B, Ballabio A. Spastic paraplegia and OXPHOS impairment caused by mutations in paraplegin, a nuclear-encoded mitochondrial metalloprotease. Cell 1998;93:973-983.
137. Ferreirinha F, Quattrini A, Pirozzi M, Valsecchi V, Dina G, Broccoli V, Auricchio A, Piemonte F, Tozzi G, Gaeta L, Casari G, Ballabio A, Rugarli EI. Axonal degeneration in paraplegin-deficient mice is associated with abnormal mitochondria and impairment of axonal transport. J Clin Invest 2004;113:231-242.
138. Yoneda T, Benedetti C, Urano F, Clark SG, Harding HP, Ron D. Compartment-specifi c perturbation of protein handling activates genes encoding mitochondrial chaperones. J Cell Sci 2004;117: 4055-4066.
139. Hansen JJ, Durr A, Cournu-Rebeix I, Georgopoulos C, Ang D, Nielsen MN, Davoine CS, Brice A, Fontaine B, Gregersen N, Bross P. Hereditary spastic paraplegia SPG13 is associated with a mutation in the gene encoding the mitochondrial chaperonin Hsp60. Am J Hum Genet 2002;70:1328-1332.
140. James PA, Talbot K. The molecular genetics of non-ALS motor neuron disease. Biochim Biophys Acta 2006;1762(11-12):986-1000.
141. Rainier S, Chai J, Tokarz D, Nicholls RD, Fink JK. NIPA1 gene mutations cause autosomal dominant hereditary spastic paraplegia (SPG6). Am J Hum Genet 2003;73:967-971.
142. Zhao J, Matthies DS, Nass R, Blakely RD, Hedera P. C. elegans model of hereditary spastic paraplegia (HSP) caused by mutations in NIPA1 gene homolog. Society for Neuroscience Meeting, Atlanta, GA, October 14-18, 2006.
143. Jouet M, Rosenthal A, Armstrong G, MacFarlane J, Stevenson R, Paterson J, Metzenberg A. X-linked spastic paraplegia (SPG1), MASA syndrome and X-linked hydrocephalus result from mutations in the L1 gene. Nat Genet 1994;7:402-407.
144. Rand JB, Johnson CD. Genetic pharmacology: Interactions betwen drugs and gene products in Caenorhabditis elegans. In: Epstein HF, Shakes DC, Eds. Methods in Cell Biology: Caenorhabditis Elegans: Modern Biological Analysis of an Organism. New York: Academic Press, 1995:187-204.
145. Link EM, Hardiman G, Sluder AE, Johnson CD, Liu LX. Therapeutic target discovery using Caenorhabditis elegans. Pharmacogenomics 2000;1:203-217.
146. Nass R, Hahn MK, Jessen T, McDonald PW, Carvelli L, Blakely RD. A genetic screen in Caenorhabditis elegans for dopamine neuron insensitivity to 6-hydroxydopamine identifies dopamine transporter mutants impacting transporter biosynthesis and trafficking. J Neurochem 2005;94:774-785.
147. Matthews DJ, Kopczynski J. Using model-system genetics for drug-based target discovery. Drug Discov Today 2001;6:141-149.